Upper Airway Stimulation for Obstructive Sleep Apnea: 5-Year Outcomes

Area of Science:

• Otolaryngology
• Sleep Medicine
• Biomedical Engineering

Background:

• Obstructive sleep apnea (OSA) is a common sleep disorder.
• Continuous positive airway pressure (CPAP) is a primary treatment for OSA.
• Some patients do not tolerate or benefit from CPAP therapy.

Purpose of the Study:

• To evaluate the 5-year outcomes of upper airway stimulation (UAS) in patients with moderate to severe OSA.
• To assess the efficacy and safety of a unilateral hypoglossal nerve implant for OSA treatment.
• To determine long-term effects on sleepiness, quality of life, and respiratory parameters.

Main Methods:

• A multicenter prospective cohort study involving 126 patients with OSA.
• Patients had moderate to severe OSA, BMI <32 kg/m², and failed CPAP.
• Outcomes included apnea-hypopnea index (AHI), oxygen desaturation, sleepiness (Epworth Sleepiness Scale), quality of life, and adverse events.

Main Results:

• 71 patients completed polysomnography at 5 years.
• Significant improvements in sleepiness and quality of life were observed.
• The AHI response rate was 75% at 5 years (63% with last observation carried forward analysis).
• Serious device-related adverse events occurred in 6% of patients.

Conclusions:

• Upper airway stimulation (UAS) provides sustained improvements in sleepiness, quality of life, and respiratory outcomes for OSA patients over 5 years.
• UAS is a safe and effective treatment option for moderate to severe OSA patients who have failed CPAP.
• Hypoglossal nerve stimulation offers a long-term therapeutic benefit for select OSA populations.